Vitamin D in patients with low tumour-burden indolent non-Hodgkin lymphoma treated with rituximab therapy

Share :
Published: 4 Jan 2024
Views: 65
Rating:
Save
Dr Jonathan Friedberg - University of Rochester, Rochester, USA

Dr Jonathan Friedberg speaks to ecancer about the results from the phase III double blind, randomised Ilyad trial presented at ASH 2023. The trial evaluated a vitamin D intervention in patients with low tumour-burden indolent non-Hodgkin lymphoma along with rituximab therapy.

He explains that all patients received rituximab and were randomised so that 2/3s received vitamin D and 1/3 received a placebo.

Dr Friedberg reports that, from an efficacy perspective, the study was a negative trial and no benefit was seen with the addition of vitamin D to the rituximab. This was the case throughout the different subtypes.